A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Recruiting now · Phase 3

Conditions studied: Neoplasms, Lung

In brief

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.

Key facts

Study ID

NCT07099898

Run by

GlaxoSmithKline

People needed

420

Starts

2025-08-11

Expected to finish

2029-09-28

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants are eligible to be included in the study only if all of the following criteria apply:
• Adults >18 or the minimum legal adult age at the time the informed consent form is signed
• Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
• Has received 1 prior platinum-based systemic therapy with a PD- (L)1 inhibitor for at least 2 cycles of therapy and a chemotherapy free-interval of >30 days, with documented progression. Participants with prior tarlatamab treatment in either the first- or second-line ES-SCLC setting are eligible.
• Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.
• Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol.
• Has adequate organ function and an ECOG performance status of 0 or 1

You may not qualify if…

• Participants are excluded from the study if any of the following criteria apply:
• Pathological diagnosis of complex SCLC or transformed SCLC.
• Limited stage small cell lung cancer at diagnosis
• Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload or treatments targeting B7-H3.
• Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
• Has severe, uncontrolled or active cardiovascular disorders.
• Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.
• Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV).
• Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal/meningeal/brainstem metastasis or evidence of spinal cord metastases.
• Has any evidence of current interstitial lung disease or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high dose steroids.
• Has significant pulmonary disease or respiratory impairment (e.g., uncontrolled asthma/COPD, restrictive lung disease),
• Has active Hepatitis B or Hepatitis C

Where it is running

• GSK Investigational Site — Mar del Plata, Buenos Aires, Argentina (enrolling)
• GSK Investigational Site — Ciudad Autonoma de Buenos Aire, Argentina (enrolling)
• GSK Investigational Site — Buenos Aires, Argentina (enrolling)
• GSK Investigational Site — Rosario, Argentina (enrolling)
• GSK Investigational Site — Vicente López, Argentina (enrolling)
• GSK Investigational Site — Blacktown, New South Wales, Australia (enrolling)
• GSK Investigational Site — St Leonards, New South Wales, Australia (enrolling)
• GSK Investigational Site — Ciudad Autonoma de Buenos Aire, Argentina (enrolling)
• GSK Investigational Site — Barretos, Brazil (enrolling)
• GSK Investigational Site — CuritibaPR, Brazil (enrolling)
• GSK Investigational Site — Florianópolis, Brazil (enrolling)
• GSK Investigational Site — Porto Alegre, Brazil (enrolling)
• GSK Investigational Site — Porto Alegre, Brazil (enrolling)
• GSK Investigational Site — Rio de Janeiro, Brazil (enrolling)
• GSK Investigational Site — São Paulo, Brazil (enrolling)
• GSK Investigational Site — Pleven, Bulgaria (enrolling)
• GSK Investigational Site — Plovdiv, Bulgaria (enrolling)
• GSK Investigational Site — Rousse, Bulgaria (enrolling)
• GSK Investigational Site — Sofia, Bulgaria (enrolling)
• GSK Investigational Site — Sofia, Bulgaria (enrolling)
• GSK Investigational Site — Ottawa, Ontario, Canada (enrolling)
• GSK Investigational Site — Toronto, Ontario, Canada (enrolling)
• GSK Investigational Site — Montreal, Quebec, Canada (enrolling)
• GSK Investigational Site — Montreal, Quebec, Canada (enrolling)
• GSK Investigational Site — Vaasa, Finland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.